Our commitment to safety, compliance, and quality care.
At Mokscare, we are dedicated to providing thoughtful, evidence-based mental health treatment, including the responsible use of stimulant medications for ADHD. As federal and state guidelines around stimulant prescriptions—such as Adderall, Vyvanse, Ritalin, and Concerta—continue to evolve rapidly, our team remains committed to patient safety and regulatory compliance while ensuring continuity of care for those who benefit from these medications.
Recent changes at both the federal and state levels aim to reduce the risk of misuse and diversion of stimulant medications. However, many of these rules remain unclear or are still in the proposal stage, leading to confusion for providers, pharmacists, and patients alike. In some cases, proposed rules are expected to be followed even before formal adoption.
Despite the complexity, Mokscare remains committed to treating ADHD with the highest standard of care. We are implementing internal policies to align with national best practices and protect the well-being of our patients.
Areas of Focus and Mokscare Policy Overview
To comply with evolving regulations and support safe prescribing practices, Mokscare has implemented protocols centered around four key areas:
1. Accurate ADHD Diagnosis & Ongoing Monitoring
We are committed to ensuring stimulant medications are prescribed only when clinically appropriate. To support accurate diagnosis and treatment monitoring:
- All patients age 16 and older—both new and existing—must complete standardized ADHD psychometric testing prior to initiating or continuing stimulant therapy. This may be completed through Mokscare or a licensed outside provider.
- Patients on long-term stimulant treatment will be retested annually to provide objective evidence of continued benefit.
- Universal drug screening is not required, but may be requested when clinically indicated.
2. Safe Prescribing Practices & Dose Monitoring
To minimize risk and ensure best practices:
- Mokscare providers follow strict internal dosage guidelines that define the maximum allowable doses and quantities for all stimulant medications.
- Regular internal reviews of prescribing patterns are conducted to ensure compliance with these limits.
- Prescription Drug Monitoring Programs (PDMPs) are used routinely to prevent duplicate prescriptions or unsafe combinations.
- No early refills will be issued for stimulant medications under any circumstances.
- Patients receiving other controlled substances may not be eligible for concurrent stimulant treatment.
3. Regular Follow-Ups & In-Person Visits
Ongoing care is essential to safe and effective stimulant use. Our follow-up policy includes:
- All patients must be seen in person before starting stimulant medication.
- After initiation, patients will be seen at least once every three months for follow-up and medication management.
- Annual in-person visits are also required to continue stimulant therapy.
- Refills will not be issued if a patient has missed the required follow-up window.
4. State Licensing & Geographic Proximity
To remain compliant with licensing laws and ensure quality oversight:
- Mokscare providers will prescribe stimulant medications only to patients who live in Kansas, Missouri, or New Mexico—states where our providers are licensed.
- Prescriptions will only be sent to pharmacies located within these licensed states.
- Patients must maintain primary residence in Kansas or Missouri to remain eligible for stimulant prescriptions through Mokscare.
Our Commitment to You
Mokscare remains committed to safe, ethical prescribing practices while honoring our responsibility to help patients live well with ADHD. As guidelines continue to evolve, we will adapt accordingly—always prioritizing the safety, compliance, and quality care our patients deserve.
If you have any questions about your treatment plan or our stimulant prescribing policies, please contact our office. We’re here to help.